胰升血糖素样肽1受体激动剂注射装置改进与2型糖尿病管理  

Improvement of GLP-1 RA injection devices and management of type 2 diabetes mellitus

作　　者：郭晓蕙[1] 霍丽 GUO Xiaohui;HUO Li(Department of Endocrinology,Peking University First Hospital,Beijing 100034,Chiina)

机构地区：[1]北京大学第一医院内分泌科,100034 [2]礼来苏州制药有限公司

出　　处：《中国糖尿病杂志》2021年第7期557-560,共4页Chinese Journal of Diabetes

摘　　要：胰升血糖素样肽1受体激动剂类药物在T2DM治疗和管理中的地位逐年提升。作为注射类药物,其注射装置是影响T2DM患者起始治疗和用药依从性的重要因素。对于T2DM患者,注射装置的改进更能满足患者需求,提高治疗依从性和持续性,助力T2DM管理。Glucagon-like peptide-1 receptor agonists have been playing an ascendingly crucial role in the management of type 2 diabetes mellitus(T2 DM). As an injection therapy,the device is an important factor that affects the initial treatment and patient adherence to medication. From the perspective of T2 DM patients,based on the understanding towards the unmet clinical needs of injection therapy,the improvement on injection devices can better meet patient needs,improve patient adherence and treatment continuity,and further promote T2 DM management.

关 键 词：糖尿病 2型 注射装置 药物依从性 偏好 胰升血糖素样肽1受体激动剂 

分 类 号：R587.1[医药卫生—内分泌]